Mucosal healing with anti-TNF antibodies

Jean Baptiste Chevaux, Stephan R. Vavricka, Gerhard Rogler, P. Lakatos, Alain Schoepfer, Laurent Peyrin-Biroulet

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking. The advent of anti-tumor necrosis factor agents has changed the way of treating inflammatory bowel disease and high rates of induction and maintenance of mucosal healing can be achieved with this drug class. Mucosal healing is desirable as it may change the natural course of the disease by decreasing surgery and hospitalization rates in both ulcerative colitis and Crohn's disease.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
JournalDigestion
Volume86
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Inflammatory Bowel Diseases
Anti-Idiotypic Antibodies
Practice Management
Ulcerative Colitis
Crohn Disease
Hospitalization
Tumor Necrosis Factor-alpha
Maintenance
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Crohn's disease
  • Endoscopic indices
  • Mucosal healing
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chevaux, J. B., Vavricka, S. R., Rogler, G., Lakatos, P., Schoepfer, A., & Peyrin-Biroulet, L. (2012). Mucosal healing with anti-TNF antibodies. Digestion, 86(SUPPL. 1), 16-22. https://doi.org/10.1159/000341957

Mucosal healing with anti-TNF antibodies. / Chevaux, Jean Baptiste; Vavricka, Stephan R.; Rogler, Gerhard; Lakatos, P.; Schoepfer, Alain; Peyrin-Biroulet, Laurent.

In: Digestion, Vol. 86, No. SUPPL. 1, 10.2012, p. 16-22.

Research output: Contribution to journalArticle

Chevaux, JB, Vavricka, SR, Rogler, G, Lakatos, P, Schoepfer, A & Peyrin-Biroulet, L 2012, 'Mucosal healing with anti-TNF antibodies', Digestion, vol. 86, no. SUPPL. 1, pp. 16-22. https://doi.org/10.1159/000341957
Chevaux JB, Vavricka SR, Rogler G, Lakatos P, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion. 2012 Oct;86(SUPPL. 1):16-22. https://doi.org/10.1159/000341957
Chevaux, Jean Baptiste ; Vavricka, Stephan R. ; Rogler, Gerhard ; Lakatos, P. ; Schoepfer, Alain ; Peyrin-Biroulet, Laurent. / Mucosal healing with anti-TNF antibodies. In: Digestion. 2012 ; Vol. 86, No. SUPPL. 1. pp. 16-22.
@article{de7b6f15dd7f47a4a757724f8672186c,
title = "Mucosal healing with anti-TNF antibodies",
abstract = "Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking. The advent of anti-tumor necrosis factor agents has changed the way of treating inflammatory bowel disease and high rates of induction and maintenance of mucosal healing can be achieved with this drug class. Mucosal healing is desirable as it may change the natural course of the disease by decreasing surgery and hospitalization rates in both ulcerative colitis and Crohn's disease.",
keywords = "Crohn's disease, Endoscopic indices, Mucosal healing, Ulcerative colitis",
author = "Chevaux, {Jean Baptiste} and Vavricka, {Stephan R.} and Gerhard Rogler and P. Lakatos and Alain Schoepfer and Laurent Peyrin-Biroulet",
year = "2012",
month = "10",
doi = "10.1159/000341957",
language = "English",
volume = "86",
pages = "16--22",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Mucosal healing with anti-TNF antibodies

AU - Chevaux, Jean Baptiste

AU - Vavricka, Stephan R.

AU - Rogler, Gerhard

AU - Lakatos, P.

AU - Schoepfer, Alain

AU - Peyrin-Biroulet, Laurent

PY - 2012/10

Y1 - 2012/10

N2 - Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking. The advent of anti-tumor necrosis factor agents has changed the way of treating inflammatory bowel disease and high rates of induction and maintenance of mucosal healing can be achieved with this drug class. Mucosal healing is desirable as it may change the natural course of the disease by decreasing surgery and hospitalization rates in both ulcerative colitis and Crohn's disease.

AB - Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking. The advent of anti-tumor necrosis factor agents has changed the way of treating inflammatory bowel disease and high rates of induction and maintenance of mucosal healing can be achieved with this drug class. Mucosal healing is desirable as it may change the natural course of the disease by decreasing surgery and hospitalization rates in both ulcerative colitis and Crohn's disease.

KW - Crohn's disease

KW - Endoscopic indices

KW - Mucosal healing

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84867528208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867528208&partnerID=8YFLogxK

U2 - 10.1159/000341957

DO - 10.1159/000341957

M3 - Article

C2 - 23051722

AN - SCOPUS:84867528208

VL - 86

SP - 16

EP - 22

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - SUPPL. 1

ER -